We retain Buy recommendation on the stock of Biocon with a revised PT of Rs. 520. Biologics segment is expected to be a significant growth driver and the company is well placed to harness the opportunities emerging in global biosimilars space. Sturdy growth prospects, strong earnings visibility, healthy balance sheet position and lower debt-equity augur well for the company. The possible listing of its wholly owned subsidiary - Biocon Biologics Limited...